O.M.T
PreclinicalSmall molecule
O.M.T is one of 3 small molecule programs targeting Tricuspid Regurgitation. It is currently in Preclinical.
1
Indications
3
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Tricuspid Regurgitation
#DrugCompanyPhaseTrials
1Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
Optimal Medical Therapy
HHelios Health Institute GmbH
Preclinical
O.M.T
CCliniques universitaires Saint-Luc- Université Catholique de Louvain
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tricuspid Regurgitation1 trial
Unspecified1 trial
Non Culprit Lesion Study
Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 3·NCT02982057·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for O.M.T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details